SIRP beta 2 Protein, Human (HEK293, Fc)

SIRP beta 2 Protein, a novel positive regulator of innate immunotherapy, is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP beta 2 is expressed on myeloid cells at protein level and enhanced adhesion, differentiation, cancer cell phagocytosis and T cell activation in an in vitro setting. DAP12 is responsible for SIRP beta 2 signaling, and is recruited through a single, positive lysine residue in the transmembrane domain of SIRP beta 2. SIRP beta 2 Protein, Human (HEK293, Fc) is the recombinant human-derived SIRP beta 2 protein, expressed by HEK293 , with C-hFc labeled tag.

Signal-regulatory protein beta-2 (SIRP beta 2), a novel positive regulator of innate immunotherapy, is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP family members are receptor-type transmembrane glycoproteins known to be involved in the negative regulation of receptor tyrosine kinase-coupled signaling processes. SIRP beta 2 has high homology with SIRP beta 1. SIRP beta 2 is expressed under normal physiological conditions in macrophages and granulocytes at the mRNA and protein level and that endogenous expression of SIRP beta 2 on PMNs correlated with trogocytosis of cancer cells. Furthermore, ectopic expression of SIRP beta 2 in the THP-1 monocytic cell line and in primary cord blood-derived macrophages increased adhesion, differentiation, and cancer cell phagocytosis. SIRP beta 2 recruited the immune activating adaptor protein DAP12 to positively regulate innate immunity, with a mutation of the charged lysine responsible for DAP12 interaction abrogating functional activity. Finally, ectopic expression of SIRP beta 2 on the THP-1 model enhanced surface expression of MHC-I molecules, enhanced T cell activation as seen by increased NFAT activation in a Jurkat report system and the upregulation of activation markers CD69 and CD25 and IFN-γ secretion on primary T cells^[1].

Human

HEK293

C-hFc

Q5JXA9-1 (Q33-G287)

284759  [NCBI]

Extracellular Domain

QSSRNDWQVLQPEGPMLVAEGETLLLRCMVVGSCTDGMIKWVKVSTQDQQEIYNFKRGSFPGVMPMIQRTSEPLNCDYSIYIHNVTREHTGTYHCVRFDGLSEHSEMKSDEGTSVLVKGAGDPEPDLWIIQPQELVLGTTGDTVFLNCTVLGDGPPGPIRWFQGAGLSREAIYNFGGISHPKETAVQASNNDFSILLQNVSSEDAGTYYCVKFQRKPNRQYLSGQGTSLKVKAKSTSSKEAEFTSEPATEMSPTG

Approximately 80-95 kDa,based on SDS-PAGE under reducing conditions.

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.